Journal of the American Academy of Dermatology
-
Early and complete removal of ticks using the right technique is important to reduce tick-transmitted diseases. Several chemical and mechanical detachment techniques have been described previously. ⋯ Tick detachment using tweezers, performed in an appropriate manner, is the easiest and most effective technique.
-
J. Am. Acad. Dermatol. · Jul 2016
Review Case ReportsSegmental stiff skin syndrome (SSS): A distinct clinical entity.
Stiff skin syndrome (SSS) is a noninflammatory, fibrosing condition of the skin, often affecting the limb girdles. ⋯ We propose a distinct clinical entity, segmental SSS, characterized by a segmental distribution, later age of onset, and less severe functional limitation. Both segmental SSS and widespread SSS share common diagnostic histopathologic features.
-
J. Am. Acad. Dermatol. · Jul 2016
ReviewCutaneous manifestations of IgG4-related disease (RD): A systematic review.
IgG4-related disease (RD) is a recently described fibroinflammatory condition with both cutaneous and systemic manifestations. To our knowledge, the cutaneous manifestations have not been well characterized or systematically investigated to date in the literature. ⋯ Papules, plaques, and nodules of the head and neck appear to characterize patients with cutaneous IgG4-RD, which nevertheless usually presents with systemic manifestations.
-
J. Am. Acad. Dermatol. · Jun 2016
Multicenter Study Observational StudyORBIT (Outcome and Retention Rate of Biologic Treatments for Psoriasis): A retrospective observational study on biologic drug survival in daily practice.
Biologic drug survival in psoriasis reflects long-term performance in real-life settings. Previous studies have yielded inconsistent results. ⋯ These findings can facilitate the daily treatment of psoriatic patients and promote long-term effectiveness of biologic therapies.
-
J. Am. Acad. Dermatol. · May 2016
Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: Long-term efficacy and safety results from 2 randomized phase-III studies and 1 open-label long-term extension study.
Tofacitinib is an oral Janus kinase inhibitor being investigated for psoriasis. ⋯ Oral tofacitinib demonstrated sustained efficacy in patients with psoriasis through 2 years, with 10 mg BID providing greater efficacy than 5 mg BID. No unexpected safety findings were observed.